Company
United StatesPublic company, NYSE: EBSEMERGENT BIOSOLUTIONS, INC. (NYSE: EBS), Gaithersburg, MD – FDA Inspections
Inspection records and compliance data for EMERGENT BIOSOLUTIONS, INC. in Gaithersburg, Maryland. 1 FDA inspection on record, last inspected September 02, 2022. Publicly traded as NYSE: EBS.
Company Profile
This profile covers EMERGENT BIOSOLUTIONS, INC. based in Gaithersburg, Maryland, United States.
FDA Inspection History
- FDA inspections
- 1
- OAI
- 0
- VAI
- 0
- NAI
- 1
- Form 483s
- 0
- Warning letters
- 0
Inspected September 2, 2022.
FDA inspections (1)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| September 2, 2022 | NAI | Human Drugs · Bioresearch Monitoring | 1180575 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
EMERGENT BIOSOLUTIONS, INC.
Stock ticker
EBS
Exchange
NYSE
Share price
$5.84
Market cap
$300.0M
Price as of
November 6, 2026
FEI Number
3012830614
Address
400 Professional Dr Ste 400, Gaithersburg, Maryland 20879, United States
Country
United States
ID: 926d87ea-bdae-4270-94dd-945b384b4fb4